Lupus Therapeutics Announces Partnership With Nkarta, Inc. To Support The Evaluation Of Natural Killer Cell Therapy in Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Lupus Therapeutics, an affiliate of the Lupus Research Alliance, has announced a partnership with Nkarta, Inc. (NASDAQ:NKTX) to support the development of NKX019, a natural killer (NK) cell therapy for refractory lupus nephritis. This is the first time the therapy, currently being studied in oncology, will be evaluated for lupus nephritis. Lupus Therapeutics will provide advisory services and support Nkarta in early development.
October 17, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nkarta, Inc. is partnering with Lupus Therapeutics to develop a new therapy for lupus nephritis. This partnership could potentially boost Nkarta's profile and value.
The partnership with Lupus Therapeutics could potentially lead to the development of a new, effective therapy for lupus nephritis. This could increase Nkarta's value and attractiveness to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100